Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
J Dermatolog Treat. 2022 Nov;33(7):3060-3062. doi: 10.1080/09546634.2022.2089336. Epub 2022 Jul 10.
Hidradenitis suppurativa (HS) is an inflammatory dermatosis for which the treatment paradigm is rapidly expanding. We aimed to identify HS patient perspectives and barriers on biologics.
An anonymous survey was distributed between 10/2021 and 1/2022 through HS support groups. Data regarding demographics and perspectives on biologics were collected and analyzed.
Of the 196 respondents, 92% were female (180/196) and 75% were white (147/196). 89.3% had Hurley stage 2/3 HS (102/195). The primary healthcare provider (HCP) for HS in 65% (128/196) of patients was a dermatologist, with 12% (23/196) seen at an HS specialty clinic. Most respondents never tried a biologic medicine (62%, 118/192). The top barriers to biologics were fear of side effects (61%, 109/179), high cost/lack of insurance coverage (46%, 83/179), frequency of weekly injections (32%, 58/179). Respondents reporting their main HCP as a non-dermatologist (4.11 vs 3.0, < .0001) and not seen at a HS specialty clinic (3.5 vs 2.7, 0.039) were significantly more likely to agree 'I do not know enough about how biologics work to help my HS'.
Our results highlight the importance of specialty care in the education and implementation of biologics. Patients may benefit from comprehensive discussion prior to starting biologics.
化脓性汗腺炎（HS）是一种炎症性皮肤病，其治疗模式正在迅速扩展。我们旨在确定 HS 患者对生物制剂的看法和障碍。
通过 HS 支持小组，于 2021 年 10 月至 2022 年 1 月期间分发匿名调查。收集并分析有关人口统计学数据和对生物制剂的看法的数据。
在 196 名受访者中，92%为女性（180/196），75%为白人（147/196）。89.3%的人患有 Hurley 2/3 期 HS（102/195）。65%（128/196）的患者的 HS 初级保健提供者（HCP）为皮肤科医生，12%（23/196）在 HS 专科诊所就诊。大多数受访者从未尝试过生物医学药物（62%，118/192）。生物制剂的主要障碍是对副作用的恐惧（61%，109/179），费用高/缺乏保险覆盖（46%，83/179），每周注射的频率（32%，58/179）。报告其主要 HCP 为非皮肤科医生的受访者（4.11 比 3.0，<0.0001）和未在 HS 专科诊所就诊的受访者（3.5 比 2.7，0.039）更有可能同意“我对生物制剂如何治疗我的 HS 了解不足”。
我们的结果强调了专科护理在生物制剂的教育和实施中的重要性。在开始使用生物制剂之前，患者可能会受益于全面的讨论。
